885950-46-9

Basic information

• Product Name: 5-Iodo-6-oxo-1,6-dihydro-pyridine-3-carboxylic acid Methyl ester
• Synonyms: 5-Iodo-6-oxo-1,6-dihydro-pyridine-3-carboxylic acid Methyl ester;Methyl 1,6-dihydro-5-iodo-6-oxonicotinate, 1,2-Dihydro-3-iodo-5-(methoxycarbonyl)-2-oxopyridine;methyl 5-iodo-6-oxo-1,6-dihydropyridine-3-carboxylate
• CAS NO: 885950-46-9
• Molecular Formula: C₇H₆INO₃
• Molecular Weight: 279.03191
• EINECS: -0
• Mol File: 885950-46-9.mol

Chemical Properties

• Melting Point: 209～211℃
• Appearance: /
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• CAS DataBase Reference: 5-Iodo-6-oxo-1,6-dihydro-pyridine-3-carboxylic acid Methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 5-Iodo-6-oxo-1,6-dihydro-pyridine-3-carboxylic acid Methyl ester(885950-46-9)
• EPA Substance Registry System: 5-Iodo-6-oxo-1,6-dihydro-pyridine-3-carboxylic acid Methyl ester(885950-46-9)

Safety Data

• Hazardous Substances Data: 885950-46-9(Hazardous Substances Data)

Usage

Uses

Used in Medicinal Chemistry:
5-Iodo-6-oxo-1,6-dihydro-pyridine-3-carboxylic acid Methyl ester is utilized as a chemical intermediate for the synthesis of various pharmaceutical compounds. Its unique structural features and reactivity make it a valuable building block in the development of new drugs and therapeutic agents.
Used in Research and Development:
In the pharmaceutical industry, 5-Iodo-6-oxo-1,6-dihydro-pyridine-3-carboxylic acid Methyl ester serves as a key component in research and development efforts. It is employed in the design and synthesis of novel drug candidates, contributing to the advancement of medicinal chemistry and the discovery of innovative treatments for various diseases and conditions.
Used in Drug Synthesis:
5-Iodo-6-oxo-1,6-dihydro-pyridine-3-carboxylic acid Methyl ester is used as a starting material in the synthesis of various pharmaceutical compounds. Its presence in the molecular structure can impart specific properties and functionalities to the resulting drug molecules, enhancing their therapeutic potential and efficacy.
Used in Drug Design:
In the field of drug design, 5-Iodo-6-oxo-1,6-dihydro-pyridine-3-carboxylic acid Methyl ester is employed as a structural element in the creation of new drug molecules. Its unique features can be leveraged to improve the pharmacokinetic and pharmacodynamic properties of drug candidates, leading to the development of more effective and safer medications.
Used in Chemical Synthesis:
Beyond its applications in medicinal chemistry, 5-Iodo-6-oxo-1,6-dihydro-pyridine-3-carboxylic acid Methyl ester can also be used in various chemical synthesis processes. Its reactivity and structural characteristics make it a versatile building block for the production of a wide range of chemical compounds and materials.

Upstream product

• 66171-50-4 methyl 6-hydroxynicotinate 
• 67-56-1 methanol 
• 5006-66-6 6-hydroxy-3-pyridinecarboxylic acid 

Downstream Products

• 1391132-73-2 C₁₆H₁₇NO₄S 
• 1391132-72-1 C₁₆H₁₇NO₄S 
• 1007170-49-1 methyl 5-[3-(benzyloxy)-4-chlorophenyl]-6-oxo-1,6-dihydropyridine-3-carboxylate 
• 1346446-87-4 (3,4-dihydro-2H-pyrano[2,3-b]pyridin-6-yl)methanol 
• 1360952-35-7 methyl 6-chloro-5-(trifluoromethyl)nicotinate 
• 73781-91-6 6-Chloronicotinic acid methyl ester 
• 56055-54-0 methyl 2,3-dichloro-pyridine-5-carboxylate 
• 1361567-63-6 C₁₃H₈Cl₃NO₂ 
• 365413-29-2 6-chloro-5-iodonicotinic acid methyl ester 
• 1373754-96-1 5-(3,4-dichloro-phenyl)-6-(2,2,2-trifluoro-ethoxy)-nicotinic acid 
• 1361748-71-1 6-chloro-5-(3,4-dichloro-phenyl)-nicotinic acid 
• 1269826-44-9 5-(3,4-dichlorophenyl)-N-((1R,2R)-2-hydroxycyclohexyl)-6-(2,2,2-trifluoroethoxy)nicotinamide 
• 122534-94-5 furo[2,3-b]pyridine-5-carboxylic acid 

Relevant articles and documents

Imidazole-containing condensed tricyclic compound and application thereof

The invention discloses an imidazole-containing condensed tricyclic compound adopting the structure as shown in the formula (I) or pharmaceutically acceptable salts, stereisomers or prodrug molecules thereof. The imidazole-containing condensed tricyclic compound has the IDO1 activity regulation function, can enhance T-cell activation through blocking immune checkpoints IDO1, is used for treating IDO1-mediated immunosuppression, and therefore, can become an effective medicine for treating malignant tumors. When used together with checkpoint protein anti-body drugs or other anti-cancer drugs, the imidazole-containing condensed tricyclic compound can enhance the anti-cancer effect. Meanwhile, the imidazole-containing condensed tricyclic compound has the potential of effectively treating IDO1 abnormity related immunosuppressive diseases and has a high application value.

Development of a safe and economical synthesis of methyl 6-chloro-5-(trifluoromethyl)nicotinate: Trifluoromethylation on kilogram scale

Reported herein is a safe and economical synthesis of methyl 6-chloro-5-(trifluoromethyl)nicotinate, an intermediate in the synthesis of novel anti-infective agents. The key to this process is the trifluoromethylation of an aryl iodide using an inexpensive methyl chlorodifluoroacetate (MCDFA)/KF/CuI system, with an emphasis on the development work which led to this effective process.

PROCESS FOR THE PREPARATION OF NICOTINAMIDE DERIVATIVES

The present invention relates to a process for the preparation of nicotinamide derivatives of the formula (I) R1 to R7 are as defined in the and to pharmaceutically acceptable salts thereof. The compounds of formula (I) are useful for the treatment and / or prophylaxis of diseases which are associated with the modulation of cannabinoid 1 receptors (CB 1 receptors) as described in the PCT Publ. WO 2006/106054.

PROCESS FOR THE PREPARATION OF NICOTINAMIDE DERIVATIVES

The present invention relates to a process for the preparation of nicotinamide derivatives of formula I, wherein R1 to R7 are as defined above and to pharmaceutically acceptable salts thereof. The compounds of formula I are useful for the treatment and/or prophylaxis of diseases which are associated with the modulation of cannabinoid 1 receptors (CB1 receptors) as described in the PCT Publ. WO 2006/106054.

Discovery of N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]furo[2,3-c]pyridine-5- carboxamide, an agonist of the α7 nicotinic acetylcholine receptor, for the potential treatment of cognitive deficits in schizophrenia: Synthesis and structure-activity relationship

N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]furo[2,3-c]pyridine-5-carboxamide (14, PHA-543,613), a novel agonist of the α7 neuronal nicotinic acetylcholine receptor (α7 nAChR), has been identified as a potential treatment of cognitive deficits in schizophrenia. Compound 14 is a potent and selective a7 nAChR agonist with an excellent in vitro profile. The compound is characterized by rapid brain penetration and high oral bioavailability in rat and demonstrates in vivo efficacy in auditory sensory gating and, in an in vivo model to assess cognitive performance, novel object recognition.